Olmesartan/Hydrochlorothiazide
Brand name: Olmesartan-Hydrochlorothiazide
Rank #497 of 500 drugs by total cost
$13.9M
Total Cost
246,637
Total Claims
$13.9M
Total Cost
9,410
Prescribers
$56
Cost per Claim
30,154
Beneficiaries
595,185
30-Day Fills
$1,476
Avg Cost/Provider
26
Avg Claims/Provider
About Olmesartan/Hydrochlorothiazide
Olmesartan/Hydrochlorothiazide (sold as Olmesartan-Hydrochlorothiazide) was prescribed 246,637 times by 9,410 Medicare Part D providers in 2023, costing the program $13.9M. At $56 per claim, this is a relatively affordable medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 494 | Binimetinib (Mektovi) | $14.1M | 1,094 |
| 495 | Glecaprevir/Pibrentasvir (Mavyret) | $14.1M | 1,011 |
| 496 | Pacritinib Citrate (Vonjo) | $13.9M | 626 |
| 497 | Olmesartan/Hydrochlorothiazide (Olmesartan-Hydrochlorothiazide) | $13.9M | 246,637 |
| 498 | C1 Esterase Inhibitor, Recomb (Ruconest) | $13.8M | 155 |
| 499 | Sildenafil Citrate (Sildenafil Citrate) | $13.8M | 248,961 |
| 500 | Lovastatin (Lovastatin) | $13.6M | 981,262 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology